BRPI0514250A - uso de um composto, composição farmacêutica que compreende o mesmo, compostos e método de tratamento - Google Patents
uso de um composto, composição farmacêutica que compreende o mesmo, compostos e método de tratamentoInfo
- Publication number
- BRPI0514250A BRPI0514250A BRPI0514250-4A BRPI0514250A BRPI0514250A BR PI0514250 A BRPI0514250 A BR PI0514250A BR PI0514250 A BRPI0514250 A BR PI0514250A BR PI0514250 A BRPI0514250 A BR PI0514250A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- compound
- pharmaceutical composition
- same
- treatment
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- VTQGYRVGBASLDF-UHFFFAOYSA-N 4-aminoazepan-2-one Chemical compound NC1CCCNC(=O)C1 VTQGYRVGBASLDF-UHFFFAOYSA-N 0.000 abstract 1
- -1 adamantariomethyl Chemical group 0.000 abstract 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 abstract 1
- 150000001602 bicycloalkyls Chemical group 0.000 abstract 1
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000005592 polycycloalkyl group Polymers 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
- C07D223/10—Oxygen atoms attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0417863A GB2418425B (en) | 2004-08-11 | 2004-08-11 | Anti-inflammatory agents |
| PCT/GB2005/003133 WO2006016152A1 (en) | 2004-08-11 | 2005-08-10 | Anti-inflammatory agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0514250A true BRPI0514250A (pt) | 2008-06-03 |
Family
ID=33017302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0514250-4A BRPI0514250A (pt) | 2004-08-11 | 2005-08-10 | uso de um composto, composição farmacêutica que compreende o mesmo, compostos e método de tratamento |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7691845B2 (enExample) |
| EP (1) | EP1781299B1 (enExample) |
| JP (2) | JP4991540B2 (enExample) |
| KR (1) | KR101341965B1 (enExample) |
| CN (1) | CN101014347B (enExample) |
| AT (1) | ATE492280T1 (enExample) |
| AU (1) | AU2005271062B2 (enExample) |
| BR (1) | BRPI0514250A (enExample) |
| CA (1) | CA2576257C (enExample) |
| DE (1) | DE602005025493D1 (enExample) |
| DK (1) | DK1781299T3 (enExample) |
| ES (1) | ES2357588T3 (enExample) |
| GB (1) | GB2418425B (enExample) |
| IL (1) | IL181055A (enExample) |
| MX (1) | MX2007001626A (enExample) |
| NO (1) | NO20071321L (enExample) |
| NZ (1) | NZ553718A (enExample) |
| PL (1) | PL1781299T3 (enExample) |
| RU (2) | RU2410376C2 (enExample) |
| WO (1) | WO2006016152A1 (enExample) |
| ZA (1) | ZA200700827B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2418425B (en) | 2004-08-11 | 2008-09-03 | Univ Cambridge Tech | Anti-inflammatory agents |
| GB2418427A (en) | 2004-09-02 | 2006-03-29 | Univ Cambridge Tech | Ligands for G-protein coupled receptors |
| GB0512238D0 (en) * | 2005-06-15 | 2005-07-27 | Univ Cambridge Tech | Anti-inflammatory agents |
| GB2430674B (en) * | 2005-08-10 | 2010-11-17 | Univ Cambridge Tech | Anti-inflammatory agents |
| US7803794B2 (en) | 2005-06-15 | 2010-09-28 | Cambridge Enterprise Limited | Anti-inflammatory agents |
| GB2451451A (en) * | 2007-07-30 | 2009-02-04 | Inion Ltd | Osteogenic compounds |
| US7662967B2 (en) | 2007-08-02 | 2010-02-16 | Cambridge Enterprise Limited | Anti-inflammatory compounds and compositions |
| GB2452696B (en) | 2007-08-02 | 2009-09-23 | Cambridge Entpr Ltd | 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions |
| GB2455539B (en) * | 2007-12-12 | 2012-01-18 | Cambridge Entpr Ltd | Anti-inflammatory compositions and combinations |
| GB201009603D0 (en) | 2010-06-08 | 2010-07-21 | Cambridge Entpr Ltd | Anti-inflammatory agent |
| CN105367495B (zh) * | 2014-08-29 | 2019-07-23 | 中国人民解放军第二军医大学 | 含有七元内酰胺环的荜拔酰胺类似物及其制备与应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7216662A (enExample) * | 1972-12-08 | 1974-06-11 | ||
| DE2758822C2 (de) * | 1977-12-30 | 1987-01-15 | Diehl GmbH & Co, 8500 Nürnberg | Verfahren zur Herstellung eines Kupfer-Zink-Werkstoffes |
| DE3217373A1 (de) * | 1982-05-08 | 1983-11-10 | Bayer Ag, 5090 Leverkusen | Sulfinyl- und sulfonyl-azacycloheptan-2-one, verfahren zu ihrer herstellung sowie ihre verwendung als futterzusatzstoffe |
| US4908445A (en) * | 1989-01-09 | 1990-03-13 | Harbor Branch Oceanographic Institution, Inc. | Sesquiterpene compounds and pharmaceutical compositions containing same, from pachastrella sponges |
| IT1247698B (it) * | 1990-06-21 | 1994-12-30 | Sigma Tau Ind Farmaceuti | 1-alchil-3-(acilammino)-e-caprolattami quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti |
| GB9026256D0 (en) * | 1990-12-03 | 1991-01-16 | Fujisawa Pharmaceutical Co | Hexahydroazepine derivatives |
| CA2173468A1 (en) * | 1993-10-21 | 1995-04-27 | Donald W. Hansen, Jr. | Amidino derivatives useful as nitric oxide synthase inhibitors |
| JP3633060B2 (ja) | 1995-09-22 | 2005-03-30 | Ｊｓｒ株式会社 | 低結晶性エチレン系ランダム共重合体およびその組成物 |
| AU5501598A (en) * | 1996-12-20 | 1998-07-17 | Astra Pharmaceuticals Limited | Triazolo{4,5-(d)}pyrimidinyl derivatives and their use as medicaments |
| JP3690052B2 (ja) * | 1997-03-24 | 2005-08-31 | Ｊｓｒ株式会社 | オイルゲル化剤 |
| JP2003146972A (ja) * | 2001-11-14 | 2003-05-21 | Teikoku Hormone Mfg Co Ltd | カルボスチリル誘導体 |
| KR100606102B1 (ko) * | 2002-08-03 | 2006-07-28 | 삼성전자주식회사 | 방송/통신 통합형 수동 광네트웍 시스템 |
| WO2004022536A1 (en) * | 2002-09-04 | 2004-03-18 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
| US7326677B2 (en) | 2003-07-11 | 2008-02-05 | The Procter & Gamble Company | Liquid laundry detergent compositions comprising a silicone blend of non-functionalized and amino-functionalized silicone polymers |
| WO2005077900A1 (ja) | 2004-02-18 | 2005-08-25 | Kyorin Pharmaceutical Co., Ltd. | ビシクロアミド誘導体 |
| GB2418425B (en) | 2004-08-11 | 2008-09-03 | Univ Cambridge Tech | Anti-inflammatory agents |
| US20120040160A1 (en) * | 2007-01-29 | 2012-02-16 | Guardian Industries Corp. | Method of making heat treated and ion-beam etched/milled coated article using diamond-like carbon (dlc) protective film |
| US20120015195A1 (en) * | 2007-01-29 | 2012-01-19 | Guardian Industries Corp. and C.R.V.C. | Method of making heat treated and ion-beam etched/milled coated article using diamond-like carbon (dlc) coating and protective film |
| US20120015196A1 (en) * | 2007-01-29 | 2012-01-19 | Guardian Industries Corp. | Method of making heat treated coated article using diamond-like carbon (dlc) coating and protective film on acid-etched surface |
-
2004
- 2004-08-11 GB GB0417863A patent/GB2418425B/en not_active Expired - Fee Related
-
2005
- 2005-08-10 WO PCT/GB2005/003133 patent/WO2006016152A1/en not_active Ceased
- 2005-08-10 BR BRPI0514250-4A patent/BRPI0514250A/pt not_active IP Right Cessation
- 2005-08-10 AU AU2005271062A patent/AU2005271062B2/en not_active Revoked
- 2005-08-10 JP JP2007525348A patent/JP4991540B2/ja not_active Expired - Lifetime
- 2005-08-10 CN CN2005800301864A patent/CN101014347B/zh not_active Expired - Lifetime
- 2005-08-10 DK DK05794153.6T patent/DK1781299T3/da active
- 2005-08-10 US US11/573,637 patent/US7691845B2/en not_active Expired - Fee Related
- 2005-08-10 RU RU2007104519/04A patent/RU2410376C2/ru not_active IP Right Cessation
- 2005-08-10 PL PL05794153T patent/PL1781299T3/pl unknown
- 2005-08-10 NZ NZ553718A patent/NZ553718A/en not_active IP Right Cessation
- 2005-08-10 DE DE602005025493T patent/DE602005025493D1/de not_active Expired - Lifetime
- 2005-08-10 CA CA2576257A patent/CA2576257C/en not_active Expired - Fee Related
- 2005-08-10 AT AT05794153T patent/ATE492280T1/de active
- 2005-08-10 MX MX2007001626A patent/MX2007001626A/es active IP Right Grant
- 2005-08-10 EP EP05794153A patent/EP1781299B1/en not_active Revoked
- 2005-08-10 ES ES05794153T patent/ES2357588T3/es not_active Expired - Lifetime
-
2007
- 2007-01-29 ZA ZA200700827A patent/ZA200700827B/xx unknown
- 2007-01-30 IL IL181055A patent/IL181055A/en not_active IP Right Cessation
- 2007-02-15 KR KR1020077003701A patent/KR101341965B1/ko not_active Expired - Fee Related
- 2007-03-12 NO NO20071321A patent/NO20071321L/no not_active Application Discontinuation
-
2010
- 2010-03-17 US US12/726,311 patent/US8497261B2/en not_active Expired - Fee Related
- 2010-10-15 RU RU2010142847/04A patent/RU2010142847A/ru not_active Application Discontinuation
-
2012
- 2012-02-23 JP JP2012037773A patent/JP2012140444A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012023382A2 (pt) | compostos, composições e métodos de uso de imidazopiridina. | |
| ECSP067076A (es) | Derivados de pirimidina urea como inhibidores de la quinasa | |
| BRPI0514250A (pt) | uso de um composto, composição farmacêutica que compreende o mesmo, compostos e método de tratamento | |
| UA94942C2 (ru) | Фармацевтические композиции с ингибиторами dpp iv | |
| BR0315580A (pt) | Derivados de metileno uréia | |
| BRPI0410669A (pt) | inibidores de caspase e usos dos mesmo | |
| BRPI0415053B8 (pt) | inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo | |
| BR112023022496A2 (pt) | Composto heterocíclico contendo nitrogênio, método de preparação do mesmo, e aplicação do mesmo em medicamentos | |
| BRPI0315958B8 (pt) | composto, composição farmacêutica, processo para a preparação de um composto, novos intermediários e uso do composto | |
| MX2022008487A (es) | Degradadores de smarca2-vhl. | |
| MY206262A (en) | Macrocyclic tyrosine kinase inhibitor and uses thereof | |
| BRPI0516077A (pt) | composições antimicrobianas compreendendo um agente natural selecionado de ácido gálico, eucalipotol, naringina, um composto de ácido jasmÈnico e qualquer combinação destes | |
| BRPI0518096A (pt) | composto, composição farmacêutica, uso de um composto para a preparação de um medicamento para o tratamento de uma condição resultante de uma anormalidade na produção de óxido nìtrico, uso de um composto para a preparação de um medicamento para o tratamento da dor em um indivìduo com necessidade do mesmo e uso de um composto para a preparação de um medicamento para o tratamento de inibição da dimerização de inos | |
| BR112022006608A2 (pt) | Inibidores orais do fator d do complemento | |
| NZ592392A (en) | PHENANTHROINDOLIZIDINE COMPOUND AND NFkB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT | |
| BR112023021030A2 (pt) | Inibidores heteroaromáticos bicíclicos de klk5 | |
| BRPI0409881A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| BRPI0511999A (pt) | compostos como antagonistas de ccr5 | |
| BRPI0720251B8 (pt) | derivado de quinolina, sua composição farmacêutica, seu uso, combinação e produto compreendendo o mesmo | |
| BRPI0509667B8 (pt) | composto, processo para a preparação de um composto de fórmula (i), medicamento e uso de um composto | |
| DE602005025228D1 (de) | Entzündungshemmende wirkstoffe | |
| ATE524180T1 (de) | Mittel zur prophylaxe oder behandlung von alkoholabhängigkeit oder drogenabhängigkeit | |
| BRPI0415546A (pt) | composto, composição farmacêutica, uso de um composto, e, métodos de tratamento ou profilaxia de doenças ou condições humanas, e de distúrbios | |
| DE602004008440D1 (de) | Pharmazeutische kombinationspräparat zur behandlung von spastischkeit und/oder schmerzen | |
| WO2006097472A3 (en) | Novel inhibitors of glutathione-s-transferase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2266 DE 10/06/2014. |